International Cancer Institute hosted members of IQVIA for a site initiation visit (SIV) of the SKYSCRAPER clinical trial at the ICI main campus in Eldoret on 15th June 2023. ICI will participate in the SKYSCRAPER Phase II/III non-squamous non-small-cell lung cancer.
During the visit, the team went through the protocols of the SKYSCRAPER clinical trial study, inclusion and exclusion criteria for study participants, data management and entry training, and assessment of ICI’s state-of-the-art facilities, among others. All ICI staff participated in the training and visit activities to ensure patients that will enroll in the study will receive the best care.
Patients interested in enrolling for the clinical trials can write to email@example.com or firstname.lastname@example.org to determine if they qualify. Clinical trials provide an alternative and the most current treatment for cancer.